樂普醫療(300003.SZ):2020年度淨利預增0%-15%
格隆匯 1 月 30日丨樂普醫療(300003.SZ)披露2020年年度業績預吿,預計2020年年度歸屬於上市公司股東的淨利潤17.25億元–19.84億元,同比增長0%-15%;歸屬於上市公司股東的扣除非經常性損益的淨利潤13.65億元–16.13億元,同比增長10%-30%。業績變動原因如下:
1、2020年前三季度公司經營正常,累計實現未經審計的扣除非經常性損益歸屬上市公司股東的淨利潤15.97億元。
2、四季度,國家組織冠脈支架集中帶量採購,由於經銷商對集採的預期以及公司消化渠道的規劃,支架產品實現很少銷售。同時,渠道中存在的已售但未植入支架,公司有可能將通過退貨或價格調整等方式予以處理,由此將形成大額損失計提。
四季度進一步加大研發投入,推進經導管主動脈瓣膜置換術(TAVR)、經導管二尖瓣修復系統、冷凍球囊、腎動脈消融導管、聲波球囊、切割球囊、可降解封堵器系列產品、連續血糖監測系統、FFR導管、人工智能心電圖機、監護儀等產品的研發進程,大幅增加研發支出。支架以外的其他業務,均延續正常運營趨勢。
由於支架集採的影響和創新產品研發的大幅支出,儘管其他業務穩定增長,公司在第四季度有可能出現虧損。綜合上述全年的業務情況,預計2020年公司實現扣除非經常性損益的歸屬於上市公司股東的淨利潤較去年同期的12.41億元約有10%至30%的增長。
3、2020年,預計非經常性損益對公司歸屬於上市公司股東的淨利潤影響金額約為4億元,與上年同期的4.85億元相比有所下降。非經常性損益項目主要包括確認上海君實生物醫藥科技股份有限公司相關的未實現浮動收益及收到各類政府補助等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.